A modified portfolio diet complements medical management to reduce cardiovascular risk factors in diabetic patients with coronary artery disease

Clin Nutr. 2015 Jun;34(3):541-8. doi: 10.1016/j.clnu.2014.06.010. Epub 2014 Jun 28.

Abstract

Background & aims: Secondary prevention can improve outcomes in high risk patients. This study investigated the magnitude of cardiovascular risk reduction associated with consumption of a modified portfolio diet in parallel with medical management.

Design: 30 patients with type II diabetes, 6 weeks post bypass surgery received dietary counseling on a Modified Portfolio Diet (MPD) (low fat, 8 g/1000 kcal viscous fibres, 17 g/1000 kcal soy protein and 22 g/1000 kcal almonds). Lipid profiles, endothelial function and markers of glycemic control, oxidative stress and inflammation were measured at baseline and following two and four weeks of intervention. Seven patients with no diet therapy served as time controls.

Results: Consumption of the MPD resulted in a 19% relative reduction in LDL (1.9 ± 0.8 vs 1.6 ± 0.6 mmol/L, p < 0.001) with no change in HDL cholesterol. Homocysteine levels dropped significantly (10.1 ± 2.7 vs 7.9 ± 4 μmol/L, p = 0.006) over the study period. Flow mediated dilatation increased significantly in treated patients (3.8 ± 3.8% to 6.5 ± 3.6%, p = 0.004) while remaining constant in controls (p = 0.6). Endothelial progenitor cells numbers (CD34+, CD 133+ and UEA-1+) increased significantly following MPD consumption (p < 0.02) with no difference in migratory capacity. In contrast, time controls showed no significant changes.

Conclusion: Dietary intervention in medically managed, high risk patients resulted in important reductions in risk factors. Clinical Trials registry number NCT00462436.

Keywords: Cardiovascular risk; Diabetes; Dietary portfolio; Endothelial function; Endothelial progenitor cells; LDL cholesterol.

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Case-Control Studies
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / diet therapy*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / diet therapy*
  • Diet, Fat-Restricted
  • Dietary Fats / administration & dosage
  • Dietary Fiber / administration & dosage
  • Energy Intake
  • Female
  • Homocysteine / blood
  • Humans
  • Male
  • Middle Aged
  • Motor Activity
  • Patient Compliance
  • Pilot Projects
  • Risk Factors
  • Soybean Proteins / administration & dosage

Substances

  • Biomarkers
  • Blood Glucose
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Dietary Fats
  • Dietary Fiber
  • Soybean Proteins
  • Homocysteine

Associated data

  • ClinicalTrials.gov/NCT00462436